Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach
Our study is the first to demonstrate that PAP is a specific target for CAR-T therapy in prostate cancer, both in vitro and in vivo. We developed the CoupledCAR platform technology for solid tumor CAR-T cell therapy, enabling the expansion of tumor-targeting CAR-T cells without requiring tumor antigens and thereby enhancing their functionality against solid tumors.
Authors
- Chengfei Pu
- Guiting Han
- Beibei Jia
- Zhiyuan Cao (ORCID: https://orcid.org/0000-0002-8685-9064)
- Lei Xiao (ORCID: https://orcid.org/0000-0002-0902-0417)
- Xianyang Jiang (ORCID: https://orcid.org/0000-0002-3565-6208)
- Xiaogang Shen (ORCID: https://orcid.org/0000-0003-1738-9430)
- Xi Huang
- Wei Ding (ORCID: https://orcid.org/0000-0001-6990-8621)
- Le Tian (ORCID: https://orcid.org/0000-0002-0105-5148)
- Wensheng Wang (ORCID: https://orcid.org/0009-0009-4495-3536)
- Zhao Wu (ORCID: https://orcid.org/0000-0001-8545-7373)
- Zhipeng Huang (ORCID: https://orcid.org/0000-0002-8414-6570)
- Victor X. Lu
Institutions
- Cellular Therapeutics (United Kingdom) (GB)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/jitc-2024-011238
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.14